Medicare part D premium help ending sooner than expected, potentially raising costs

The Centers for Medicare & Medicaid Services (CMS) recently announced it would conclude the Part D Premium Stabilization Demonstration by the end of 2026, a full year ahead of its original schedule [Medicare Rights Center]. This move has significant implications for Medicare beneficiaries, particularly those with stand-alone prescription drug plans.

Understanding the Premium Stabilization Program

The Part D Premium Stabilization Demonstration was established to help manage premium costs for stand-alone Part D plans, especially as changes from the Inflation Reduction Act (IRA) took effect [Medicare Rights Center]. The IRA restructured Part D, introducing an inflation-adjusted out-of-pocket spending cap for enrollees, which is set at $2,100 for 2026 [Medicare Rights Center]. This restructuring shifted some financial responsibility to the plans, prompting many to propose higher premiums.

Impact on Beneficiaries

While the IRA was intended to reduce out-of-pocket costs for beneficiaries, particularly those with high drug expenses, it also led to an increase in proposed premiums from drug plans. The Premium Stabilization Demonstration was designed to cushion this impact and prevent premiums from rising too sharply [Medicare Rights Center]. With the program ending sooner, beneficiaries in stand-alone Part D plans may face steeper premium increases in 2027 and beyond than they might have otherwise. The CMS decision to end this program early, as announced on July 28, 2026, was part of a larger update on Parts C and D [Medicare Rights Center].

Disparity Between Plan Types

One critical aspect of this situation is the difference in how Part D costs affect various Medicare plans. Medicare Advantage plans that include Part D (MA-PDs) are not experiencing the same level of impact [Medicare Rights Center]. These plans can leverage Medicare funding to keep their premiums lower in ways that stand-alone Part D plans cannot, through mechanisms like rebates and other payments [Medicare Rights Center]. This disparity could incentivize beneficiaries to choose MA-PDs for their lower drug plan rates, even if a Medicare Advantage plan might not be the most suitable choice for their overall health needs [Medicare Rights Center].

Choosing between Original Medicare with a stand-alone Part D plan and a Medicare Advantage plan is a highly personal decision, and imbalances in how premiums are set can complicate this choice. The early termination of the Premium Stabilization Demonstration highlights the ongoing challenges in balancing beneficiary costs, plan finances, and policy objectives within the Medicare system.